AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 259: E261-E265, 1990;
0193-1849/90 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clemson, B.
Right arrow Articles by Zelis, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clemson, B.
Right arrow Articles by Zelis, R.

AJP - Endocrinology and Metabolism, Vol 259, Issue 2 E261-E265, Copyright © 1990 by American Physiological Society

ARTICLES

Effects of desipramine on norepinephrine clearance in congestive heart failure

B. Clemson, R. G. Baily, D. Davis and R. Zelis
Division of Cardiology, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey 17033.

Elevated plasma norepinephrine (NE) in congestive heart failure (CHF) is caused by increased NE spillover and decreased NE clearance. To evaluate the effects of neuronal uptake blockade on NE clearance, we studied NE kinetics during steady-state infusions of [3H]NE, before and after oral desipramine (DMI, 50 mg) in 11 patients with CHF and 8 normal volunteers. Baseline plasma NE was greater in the CHF group (637 +/- 56 vs. 271 +/- 32 pg/ml; P less than 0.001), NE clearance was lower in CHF (1.31 +/- 0.21 vs. 1.94 +/- 0.17 l.min-1.m-2; P = 0.026), and NE spillover was greater in CHF (4.71 +/- 0.78 vs. 3.04 +/- 0.35 nmol.min-1.m-2, P = 0.054). After DMI, plasma NE rose significantly in CHF (778 +/- 67; P = 0.008), and NE clearance decreased further in CHF (0.97 +/- 0.16; P = 0.024), but neither changed in normal subjects. NE spillover did not change in either group. There appears to be an enhanced effect of DMI on NE clearance in CHF patients. Two general mechanisms may be responsible for this finding, an increased concentration of drug, possibly caused by a decreased volume of distribution, and an increased sensitivity of neuronal amine pumps to DMI. Both mechanisms may reflect a more general abnormality of clearance of drugs and hormones related to abnormalities of tissue perfusion in CHF.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
C.-s. Liang, W. Mao, C. Iwai, S. Fukuoka, and S. Y. Stevens
Cardiac sympathetic neuroprotective effect of desipramine in tachycardia-induced cardiomyopathy
Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H995 - H1003.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
C.-s. Liang, A. Yatani, Y. Himura, M. Kashiki, and S. Y. Stevens
Desipramine attenuates loss of cardiac sympathetic neurotransmitters produced by congestive heart failure and NE infusion
Am J Physiol Heart Circ Physiol, May 1, 2003; 284(5): H1729 - H1736.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
G. W. Lambert, D. M. Kaye, J. Lefkovits, G. L. Jennings, A. G. Turner, H. S. Cox, and M. D. Esler
Increased Central Nervous System Monoamine Neurotransmitter Turnover and Its Association With Sympathetic Nervous Activity in Treated Heart Failure Patients
Circulation, October 1, 1995; 92(7): 1813 - 1818.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online